Bioventus Inc.
BVS · NASDAQ
9/27/2025 | 6/28/2025 | 3/29/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $138,651 | $147,660 | $123,876 | $153,642 |
| % Growth | -6.1% | 19.2% | -19.4% | – |
| Cost of Goods Sold | $45,820 | $45,570 | $40,820 | $50,986 |
| Gross Profit | $92,831 | $102,090 | $83,056 | $102,656 |
| % Margin | 67% | 69.1% | 67% | 66.8% |
| R&D Expenses | $2,923 | $3,172 | $3,011 | $3,246 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $77,804 | $79,110 | $73,502 | $86,613 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1,440 | $1,674 | $4,809 |
| Operating Expenses | $80,727 | $83,722 | $78,187 | $94,668 |
| Operating Income | $12,104 | $18,368 | $4,869 | $7,988 |
| % Margin | 8.7% | 12.4% | 3.9% | 5.2% |
| Other Income/Exp. Net | -$7,434 | -$8,055 | -$8,286 | -$7,756 |
| Pre-Tax Income | $4,670 | $10,313 | -$3,417 | $232 |
| Tax Expense | $664 | $1,041 | -$95 | $550 |
| Net Income | $3,155 | $7,459 | -$2,637 | -$156 |
| % Margin | 2.3% | 5.1% | -2.1% | -0.1% |
| EPS | 0.047 | 0.11 | -0.04 | -0.002 |
| % Growth | -57.2% | 375% | -1,900% | – |
| EPS Diluted | 0.046 | 0.11 | -0.04 | -0.002 |
| Weighted Avg Shares Out | 66,925 | 66,500 | 66,009 | 65,452 |
| Weighted Avg Shares Out Dil | 68,838 | 68,537 | 66,009 | 65,452 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $6,177 | $7,494 | $7,509 | $8,997 |
| Depreciation & Amortization | $11,403 | $12,049 | $11,865 | $12,405 |
| EBITDA | $22,250 | $29,856 | $15,957 | $21,634 |
| % Margin | 16% | 20.2% | 12.9% | 14.1% |